6XP Stock Chart & Stats
€1.33
€0.03(2.31%)
At close: 4:00 PM EDT
€1.33
€0.03(2.31%)
Day’s Range― - ―
52-Week Range€0.88 - €5.63
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€45.87M
Enterprise Value€645.43
Total Cash (Recent Filing)€179.91M
Total Debt (Recent Filing)€147.30M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.86
Shares Outstanding47,416,573
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-5.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.57
Revenue Forecast (FY)€8.67M
Bulls Say, Bears Say
Bulls Say
Moderate Leverage And Equity BaseThe substantial equity base relative to debt provides a financial cushion and limits near-term balance-sheet stress. This supports continued development activity, although ongoing losses and rising leverage could reduce that flexibility over time.
Losses Improving From 2024 TroughThe reduction in net losses from the 2024 trough indicates some improvement in financial performance. If sustained, this could extend the company’s operating runway, though losses remain substantial and commercialization has not yet been achieved.
Proprietary Oncology Formulation PlatformA proprietary formulation platform targeting known oncology drugs can potentially shorten development risk relative to discovering entirely new molecules. Improved delivery and patent protection may support differentiated products if candidates achieve approval and commercialization.
Bears Say
No Revenue And Persistent UnprofitabilityThe absence of revenue means the business has not yet demonstrated commercial traction or self-funding capacity. Persistent operating and net losses increase dependence on future financing and leave results highly exposed to delays in commercialization.
Sustained Cash Burn Requires FinancingNegative operating and free cash flow show that ongoing development consumes substantial cash rather than generating it. Continued outflows may require additional equity or debt financing, creating dilution, funding risk, and pressure to prioritize projects.
Rising Leverage Amid Negative ReturnsAlthough leverage remains moderate, its increase from earlier years is occurring alongside negative returns on equity and continuing losses. This weakens financial flexibility and could make future capital more costly or less available if markets tighten.
Xspray Pharma AB News
6XP FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was €0.88 and its highest was €5.63 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is €45.87M.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is Nov 04, 2026 which is in 68 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Aug 05, 2026. The company reported -€0.079 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 47,416,573 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -€0.079 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.036%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in DE:6XP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.
Technical Analysis
Camurus AB
―
Vicore Pharma Holding AB
―
Xbrane Biopharma AB
―
Spago Nanomedical AB
―
Bio-Works Technologies AB
―